A growing number of obese adults and children have been prescribed Ozempic or similar medications to lose weight ...

Dubbed the “King Kong” of weight loss jabs, Mounjaro, the brand name for tirzepatide ... for long-term blood sugar and appetite control. Plus, if the drug is stopped people put fat back ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

as adults with obesity or overweight plus one obesity-related comorbidity achieved greater weight loss at 72 weeks with tirzepatide vs. semaglutide. In SURMOUNT-5, adults aged 18 years and older ...

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 ...

A major 72-week trial shows tirzepatide leads to double-digit weight loss and greater waist reduction than semaglutide, reshaping obesity treatment strategies and offering new hope for patients ...

The SURMOUNT-5 trial, published over the weekend in the New England Journal of Medicine and presented at the European Congress on Obesity, showed that treatment with tirzepatide (Zepbound; Eli Lilly) ...

Compared with semaglutide and insulin, tirzepatide was associated with improved glycemic control and weight loss outcomes among patients with type 2 diabetes. Tirzepatide is associated with longer ...

Nearly one-third (32%) of the people who took tirzepatide achieved a body-weight reduction of at least 25%, compared with 16% of those who received semaglutide.

MÁLAGA, Spain — In the first head-to-head trial of its kind, tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity; Eli Lilly) produced significantly greater weight loss ...